Comparing SAHA and Paclitaxel for Ovarian Cancer Treatment
Author Information
Author(s): Sonnemann Jürgen, Gänge Jennifer, Pilz Sabine, Stötzer Christine, Ohlinger Ralf, Belau Antje, Lorenz Gerd, Beck James F
Primary Institution: Ernst Moritz Arndt University
Hypothesis
Is suberoylanilide hydroxamic acid (SAHA) more effective than paclitaxel in treating ovarian cancer cells?
Conclusion
SAHA may be more effective than paclitaxel in treating paclitaxel-resistant ovarian cancer.
Supporting Evidence
- SAHA induced cell death in all five patient-derived cancer cell isolates.
- Four of the five isolates were resistant to paclitaxel.
- SAHA increased caspase-3 activity in all five isolates, while paclitaxel did not affect three of them.
Takeaway
This study found that a new drug called SAHA can kill ovarian cancer cells that don't respond to the usual treatment, paclitaxel.
Methodology
The study compared the effects of SAHA and paclitaxel on ovarian cancer cell lines and primary cancer cells from patients, using assays to measure cell death and caspase-3 activity.
Limitations
The study had a small sample size of patient-derived cells, which may limit the generalizability of the findings.
Participant Demographics
Five patients with stage III ovarian carcinomas, four untreated and one previously treated with paclitaxel/carboplatin.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website